What ails the FDA? [3] (multiple letters)

New England Journal of Medicine

Volumn 352, Issue 24, 2005, Pages 2553-2555

  Gorelick, Kenneth J ^a   Marcus, Donald M ^b   Cohen, Fredric J ^c   Jenny Avital, Elizabeth R ^d  

^a Baylor College of Medicine ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Crownstone   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE;

DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; INSURANCE; LETTER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; ADVERTIZING; CLINICAL TRIAL; DRUG INDUSTRY; ECONOMICS; NOTE; ORGANIZATION AND MANAGEMENT; RISK ASSESSMENT; UNITED STATES;

ADVERTISING; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; LACTONES; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; SULFONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 22444433526     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM200506163522418     Document Type: Letter

References (0)